Limpid Strengthens Strategic Acquisition to Enhance Freeze-Dried Pet Food Production Capacity

Acquisition of Core Production Facilities and Business Rights of Atti Food

Bio pet food company Limpid announced on the 24th that it has acquired the core production facilities and business rights of domestic freeze-dried feed manufacturer Atti Food and has begun full-scale operations. Through this acquisition, Limpid plans to significantly expand its production capacity of freeze-dried feed and further solidify its position in the premium pet food market.

Limpid is a company that developed freeze-dried prescription feed. Prescription feed using the freeze-drying method offers a high nutrient retention rate, providing an optimized solution for managing chronic diseases in companion animals. This acquisition is expected to serve as a stepping stone for Limpid to leap beyond a simple feed manufacturer to a bio pet food company encompassing companion animal nutrition and clinical research.

Limpid has established a joint venture with Kyungpook National University to launch a feed-specialized clinical trial (CRO) institution, promoting the development of high-quality products verified through scientific validation. Through this, Limpid is actively implementing a vertical integration strategy that covers not only feed manufacturing but also precise nutrition formulation, clinical research, and production.

Limpid plans to expand its business not only in freeze-dried prescription feed but also in the premium functional feed market. Kim Hee-su, CEO of Limpid, said, “Through this acquisition, Limpid has secured independent production capabilities and established a foundation to strengthen R&D and clinical verification.”